Characterizing the collateral activity of CRISPR/Cas13 in mammalian cells: Implications for RNA editing and therapeutic applications

被引:0
|
作者
Wan, Yanbin [1 ]
Huang, Caimei [1 ]
Feng, Dongyan [1 ,2 ]
Wang, Lv [1 ]
Lin, Xiding [1 ]
Zhao, Xuanye [1 ]
Han, Liya [1 ]
Zhu, Yanyu [3 ]
Hao, Lijing [4 ]
Du, Hongli [1 ,5 ]
Huang, Lizhen [1 ,5 ]
机构
[1] South China Univ Technol, Sch Biol & Biol Engn, Guangzhou 510006, Peoples R China
[2] Bioland Lab, Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou 510530, Peoples R China
[3] Univ Calif Los Angeles, Dept Bioengn, 330 Neve Dr, Los Angeles, CA 90024 USA
[4] South China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Peoples R China
[5] South China Univ Technol, FangRui Inst Pharmaceut Innovat, Guangzhou 510006, Peoples R China
关键词
CRISPR/Cas13; Collateral activity; Mammalian cells; CRISPR-CAS13A; BACTERIA;
D O I
10.1016/j.ijbiomac.2024.137861
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The CRISPR/Cas13 system has garnered attention as a potential tool for RNA editing. However, the degree of collateral activity among various Cas13 orthologs and their cytotoxic effects in mammalian cells remain contentious, potentially impacting their applications. In this study, we observed differential collateral activities for LwaCas13a and RfxCas13d in 293T and U87 cells by applying both sensitive dual-fluorescence (mRuby/GFP) reporter and quantifiable dual-luciferase (Fluc/Rluc) reporter, with LwaCas13a displaying notable activity contrary to previous reports. However, significant collateral RNA cleavage exerted only a modest impact on cell viability. Furthermore, collateral activity of LwaCas13a mildly impeded, but did not arrest, porcine embryo development. Our findings reveal that distinct collateral RNA cleavage by Cas13 slightly suppresses mammalian cell proliferation and embryo development. This could account for the lack of reported collateral effects in numerous prior studies and offers new insights into the implications of the collateral activity of Cas13 for clinical application.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] RNA targeting with CRISPR–Cas13
    Omar O. Abudayyeh
    Jonathan S. Gootenberg
    Patrick Essletzbichler
    Shuo Han
    Julia Joung
    Joseph J. Belanto
    Vanessa Verdine
    David B. T. Cox
    Max J. Kellner
    Aviv Regev
    Eric S. Lander
    Daniel F. Voytas
    Alice Y. Ting
    Feng Zhang
    Nature, 2017, 550 : 280 - 284
  • [2] CRISPR/Cas13 as a Tool for RNA Interference
    Ali, Zahir
    Mahas, Ahmed
    Mahfouz, Magdy
    TRENDS IN PLANT SCIENCE, 2018, 23 (05) : 374 - 378
  • [3] CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells
    Lin, Ping
    Qin, Shugang
    Pu, Qinqin
    Wang, Zhihan
    Wu, Qun
    Gao, Pan
    Schettler, Jacob
    Guo, Kai
    Li, Rongpeng
    Li, Guoping
    Huang, Canhua
    Wei, Yuquan
    Gao, George Fu
    Jiang, Jianxin
    Wu, Min
    MOLECULAR CELL, 2020, 78 (05) : 850 - +
  • [4] Programmable RNA editing with compact CRISPR–Cas13 systems from uncultivated microbes
    Chunlong Xu
    Yingsi Zhou
    Qingquan Xiao
    Bingbing He
    Guannan Geng
    Zikang Wang
    Birong Cao
    Xue Dong
    Weiya Bai
    Yifan Wang
    Xiang Wang
    Dongming Zhou
    Tanglong Yuan
    Xiaona Huo
    Jinsheng Lai
    Hui Yang
    Nature Methods, 2021, 18 : 499 - 506
  • [5] CRISPR/Cas13 sgRNA-Mediated RNA-RNA Interaction Mapping in Live Cells with APOBEC RNA Editing
    Diao, Li-Ting
    Xie, Shu-Juan
    Xu, Wan-Yi
    Zhang, Hai-Hui
    Hou, Ya-Rui
    Hu, Yan-Xia
    Liang, Xin-Xiang
    Liang, Jun-Bin
    Zhang, Qi
    Xiao, Zhen-Dong
    ADVANCED SCIENCE, 2024, 11 (45)
  • [6] Engineered Cas13 with Minimal Collateral Effect and Improved Editing Efficiency for Targeted RNA Degradation
    Wang, Xing
    Zhou, Yingsi
    Tong, Huawei
    Yang, Dong
    Xiao, Qingquan
    Dong, Xue
    Liu, Yuanhua
    Yang, Hui
    MOLECULAR THERAPY, 2023, 31 (04) : 669 - 670
  • [7] Intrinsic RNA-targeting activity limits the applicability of CRISPR–Cas13
    Nature Biomedical Engineering, 2024, 8 : 116 - 117
  • [8] Engineered Cas13 variants with minimal collateral RNA targeting
    Tong, Huawei
    Yang, Hui
    NATURE BIOTECHNOLOGY, 2023, 41 (01) : 29 - 30
  • [9] Engineered Cas13 variants with minimal collateral RNA targeting
    Nature Biotechnology, 2023, 41 : 29 - 30
  • [10] Amplification-free RNA detection with CRISPR–Cas13
    Hajime Shinoda
    Yuya Taguchi
    Ryoya Nakagawa
    Asami Makino
    Sae Okazaki
    Masahiro Nakano
    Yukiko Muramoto
    Chiharu Takahashi
    Ikuko Takahashi
    Jun Ando
    Takeshi Noda
    Osamu Nureki
    Hiroshi Nishimasu
    Rikiya Watanabe
    Communications Biology, 4